lutetium has been researched along with Lymph Node Metastasis in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 5 (55.56) | 2.80 |
| Authors | Studies |
|---|---|
| Frydenberg, M; Grimes, D; McBean, R; Vasey, P; Wong, D; Yaxley, JW; Yaxley, WJ | 1 |
| Grubmüller, B; Hacker, M; Haug, AR; Kramer, G; Kretschmer-Chott, E; Mitterhauser, M; Oszwald, A; Rasul, S; Shariat, SF; Vraka, C; Wollenweber, T; Yu, J; Zisser, L | 1 |
| Freesmeyer, M; Leder, T; Seifert, P; Theis, B; Werner, A | 1 |
| Ahmadzadehfar, H; Alamdar, R; Attenberger, U; Conrad, R; Essler, M; Marinova, M; Mücke, M | 1 |
| Baum, RP; Kulkarni, HR; Singh, A; Zhang, J | 1 |
| Costa, FP; de Herder, WW; Feelders, RA; Gumz, B; Kaltsas, G; Kamp, K; Kwekkeboom, DJ | 1 |
| Ahmadzadehfar, H; Bode, A; Claesener, M; Eppard, E; Heinzel, A; Rahbar, K; Schmidt, M; Yordanova, A | 1 |
| KAWAMURA, K; KITAGAWA, S | 1 |
| Andrews, PM; Goldenberg, DM; Mattes, MJ; Michel, RB; Rosario, AV | 1 |
1 trial(s) available for lutetium and Lymph Node Metastasis
| Article | Year |
|---|---|
Improving quality of life in patients with metastatic prostate cancer following one cycle of 177Lu-PSMA-617 radioligand therapy: a pilot study.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Humans; Liver Neoplasms; Lung Neoplasms; Lutetium; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pilot Projects; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Radiopharmaceuticals; Retrospective Studies; Treatment Outcome | 2020 |
8 other study(ies) available for lutetium and Lymph Node Metastasis
| Article | Year |
|---|---|
Should Lutetium-prostate specific membrane antigen radioligand therapy for metastatic prostate cancer be used earlier in men with lymph node only metastatic prostate cancer?
Topics: Antigens, Surface; Antineoplastic Agents; Dipeptides; Glutamate Carboxypeptidase II; Heterocyclic Compounds, 1-Ring; Humans; Ligands; Lutetium; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Survival Analysis; Time-to-Treatment; Treatment Outcome; Tumor Burden | 2021 |
Response to [ 177 Lu]Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients presenting with only lymph node metastases.
Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Lymphatic Metastasis; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Retrospective Studies | 2022 |
Image-Guided Fine-Needle Aspiration Cytology for BRCA Mutation Assessment of PSMA-Positive Lymph Node Metastases in a Patient With Metastatic Castration-Resistant Prostate Cancer.
Topics: Biopsy, Fine-Needle; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Lymphatic Metastasis; Male; Middle Aged; Mutation; Positron Emission Tomography Computed Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals | 2023 |
Complete Regression of Lung Metastases in a Patient With Metastatic Castration-Resistant Prostate Cancer Using 177Lu-PSMA Radioligand Therapy.
Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lung Neoplasms; Lutetium; Lymphatic Metastasis; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2020 |
Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotate.
Topics: Adult; Aged; Bone Neoplasms; Everolimus; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Intestinal Neoplasms; Liver Neoplasms; Lutetium; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Safety; Sirolimus; Stomach Neoplasms; Survival Rate | 2013 |
Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis.
Topics: Adult; Aged; Aged, 80 and over; Dipeptides; Dose-Response Relationship, Drug; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Lymphatic Metastasis; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Radiation Injuries; Radiopharmaceuticals; Retrospective Studies; Treatment Outcome | 2016 |
STUDIES AND CLINICAL OBSERVATIONS OF INFUSION OF ANTI-CANCEROUS AGENTS INTO LYMPH VESSEL SYSTEM.
Topics: Gastrectomy; Gold Isotopes; Humans; Infusions, Parenteral; Injections, Intralymphatic; Lutetium; Lymph Node Excision; Lymphatic Metastasis; Lymphatic System; Mononuclear Phagocyte System; Radioisotopes; Serum Albumin; Serum Albumin, Radio-Iodinated; Stomach Neoplasms; Thoracic Duct; Yttrium Isotopes | 1964 |
177Lu-antibody conjugates for single-cell kill of B-lymphoma cells in vitro and for therapy of micrometastases in vivo.
Topics: Animals; Antibodies; Body Burden; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Radiation; Lutetium; Lymphatic Metastasis; Lymphoma, B-Cell; Mice; Mice, SCID; Radiation Dosage; Radioimmunotherapy; Radioisotopes; Radiometry; Radiopharmaceuticals; Relative Biological Effectiveness; Survival Analysis; Treatment Outcome | 2005 |